EFFICACY AND SAFETY OF COTADUTIDE, A DUAL GLP1-GLUCAGON RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND T2DM

被引：0
|
作者：
Selvarajah, Viknesh [1 ]
Robertson, Darren [1 ]
Hansen, Lars [2 ]
Jermutus, Lutz [1 ]
Smith, Kirsten [1 ]
Frickleton, Celeste [2 ]
Coggi, Angela [1 ]
Sanchez, Jose [3 ]
Chang, Yi-Ting [2 ]
Parker, Victoria [1 ]
机构：
[1] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Cambridge, England
[2] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Gaithersburg, MD USA
[3] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Molndal, Sweden
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
3000
引用
收藏
页码：I87 / I87
页数：1
相关论文
共 50 条
  • [21] Tolerability, Safety, Pharmacokinetics, and Therapeutic Efficacy of Once-Weekly Administration of GLP-1 Analogue in T2DM Patients
    Liu, Edy
    Guo, Xiaohui
    Tracey, Gregory
    Willett, Michael
    Lasseter, Kenneth
    Huang, Gavin
    Lv, Wei
    Zhou, Joe
    Zhang, Lihong
    Xu, Michael M.
    DIABETES, 2016, 65 : A268 - A268
  • [22] Long-Term Safety and Efficacy of Dapagliflozin in Patients with T2DM and Cardiovascular Disease
    Cefalu, William T.
    Leiter, Lawrence A.
    Johnsson, Eva
    Sugg, Jennifer
    Gause-Nilsson, Ingrid
    DIABETES, 2015, 64 : A28 - A29
  • [23] Efficacy and Tolerability of MK-0893, a Glucagon Receptor Antagonist (GRA), in Patients with Type 2 Diabetes (T2DM)
    Engel, Samuel S.
    Xu, Lei
    Andryuk, Paula J.
    Davies, Michael J.
    Amatruda, John
    Kaufman, Keith
    Goldstein, Barry J.
    DIABETES, 2011, 60 : A85 - A85
  • [24] Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes
    Asano, Michiko
    Sekikawa, Akiko
    Kim, Hyosung
    Gasser, Robert A., Jr.
    Robertson, Darren
    Petrone, Marcella
    Jermutus, Lutz
    Ambery, Philip
    DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1859 - 1867
  • [25] Real-World Persistence with GLP-1 RA Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced Chronic Kidney Disease (CKD)
    Sidra, Fnu
    Xie, Donglu
    Agarwal, Shubham
    Lingvay, Ildiko
    DIABETES, 2023, 72
  • [26] Two-Year Efficacy and Safety of Dapagliflozin for T2DM Patients with a History of Cardiovascular Disease
    Gause-Nilsson, Ingrid
    De Bruin, Tjerk W.
    Sugg, Jennifer E.
    Parikh, Shamik J.
    Johnsson, Eva
    Leiter, Lawrence A.
    DIABETES, 2014, 63 : A271 - A271
  • [27] Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks
    Yale, Jean-Francois
    Bakris, George
    Cariou, Bertrand
    Iglesias, Javier Nieto
    Wajs, Ewa
    Figueroa, Katherine
    Jiang, Joel
    Usiskin, Keith
    Meininger, Gary
    DIABETES, 2013, 62 : A277 - A278
  • [28] Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) who progressed to stage 3A chronic kidney disease during treatment
    Roussel, R.
    de Zeeuw, D.
    Law, G.
    Meininger, G.
    DIABETOLOGIA, 2014, 57 : S322 - S323
  • [29] GLP-1 RECEPTOR AGONIST TREATMENT-RELATED FEATURES IMPORTANT TO TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS: A PREFERENCE STUDY IN GERMANY
    Qin, L.
    Chen, S.
    Shaunik, A.
    Flood, E.
    Romero, B.
    de la Cruz, M.
    Alvarez, C.
    Grandy, S.
    VALUE IN HEALTH, 2016, 19 (07) : A678 - A679
  • [30] SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM
    Saroka, Rachel M.
    Kane, Michael P.
    Busch, Robert S.
    Watsky, Jay
    Hamilton, Robert A.
    ENDOCRINE PRACTICE, 2015, 21 (12) : 1315 - 1322
12345